Valuation: Nutriband Inc.

Market Cap 77.92M 69.57M 63.84M 58.07M 109M 7.38B 111M 762M 307M 3.89B 292M 286M 12.3B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 73.59M 65.7M 60.29M 54.84M 103M 6.97B 105M 720M 290M 3.68B 276M 270M 11.61B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
40.85%
Yield 2025 *
-
Yield 2026 -
1 day+1.75%
1 week+7.37%
Current month+1.75%
1 month-11.95%
3 months+124.91%
6 months+66.06%
Current year+41.19%
1 week 5.99
Extreme 5.99
6.66
1 month 5.65
Extreme 5.65
7.65
Current year 2.8
Extreme 2.8
9.19
1 year 2.8
Extreme 2.8
9.19
3 years 1.93
Extreme 1.927
11.78
5 years 1.53
Extreme 1.53
11.78
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 01/01/2016
Chief Executive Officer 52 -
Director of Finance/CFO 77 02/09/2020
Director TitleAgeSince
Chairman 52 21/01/2022
Director/Board Member 48 01/07/2018
Director/Board Member 38 01/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
31/1/25 Other

Founder

126,833 1.1420%
31/1/25 Option

Chief Financial Officer

212,837 1.9164%
20/3/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
+1.75%+7.37%-4.75%+187.44% 77.92M
+3.73%+5.03%-10.89%+14.80% 191B
+2.85%+4.75%+9.47%+37.73% 122B
+5.12%+0.22%-13.88%+10.27% 117B
+1.41%+6.80%-41.10%+6.45% 96.21B
+2.12%+2.38%+0.01%+75.79% 64.47B
-5.48%-5.11%-1.24%+61.88% 52.51B
+0.36%+1.13%+11.13%-22.40% 54.1B
+21.85%+17.79%+6.69%+60.13% 52.91B
+2.23%+4.24%+1.04%-8.32% 35.65B
Average +3.59%+4.22%-4.35%+42.38% 78.49B
Weighted average by Cap. +3.69%+3.95%-7.10%+24.27%

Financials

2025 2026
Net sales 2.14M 1.91M 1.75M 1.59M 2.99M 203M 3.05M 20.94M 8.44M 107M 8.03M 7.86M 338M 2.04M 1.82M 1.67M 1.52M 2.85M 193M 2.9M 19.93M 8.03M 102M 7.64M 7.48M 321M
Net income -10.48M -9.36M -8.59M -7.81M -14.65M -992M -14.94M -103M -41.35M -524M -39.34M -38.5M -1.65B -8.23M -7.35M -6.74M -6.13M -11.5M -779M -11.73M -80.53M -32.46M -411M -30.89M -30.23M -1.3B
Net Debt -4.13M -3.68M -3.38M -3.07M -5.76M -391M -5.88M -40.37M -16.27M -206M -15.48M -15.15M -651M -4.33M -3.87M -3.55M -3.23M -6.05M -410M -6.17M -42.37M -17.08M -216M -16.25M -15.9M -683M
Projected Income Statement - Annual - Nutriband Inc.
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
02/11/26 USD 6.410 +1.75% 14,742
30/10/26 USD 6.300 -5.12% 22,233
29/10/26 USD 6.640 +3.75% 12,615
28/10/26 USD 6.400 +7.56% 71,081
27/10/26 USD 5.950 -0.34% 11,707
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.410USD
Average target price
15.00USD
Spread / Average Target
+134.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nutriband Inc.
  1. Stock Market
  2. Stocks
  3. NTRB Stock